In Vitro and In Vivo Inhibition of the 2 Active Sites of ACE by Omapatrilat, a Vasopeptidase Inhibitor
Open Access
- 1 June 2000
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Hypertension
- Vol. 35 (6) , 1226-1231
- https://doi.org/10.1161/01.hyp.35.6.1226
Abstract
Abstract —The vasopeptidase inhibitor omapatrilat inhibits both neutral endopeptidase and angiotensin-converting enzyme (ACE). The in vitro and in vivo inhibitory potency of omapatrilat and the specific ACE inhibitor fosinopril toward the 2 active sites of ACE (called N- and C - domains) was investigated with the use of 3 substrates: angiotensin I, which is equally cleaved by the 2 ACE domains; hippuryl-histidyl-leucine, specific synthetic substrate of the C-domain in high- salt conditions; and a newly synthesized specific substrate of the N-domain designed by acetylating the lysine residue of AcSDKP. In vitro, omapatrilat was 5 times more potent than fosinoprilat in inhibiting angiotensin I hydrolysis. Omapatrilat inhibited similarly both N- and C-domain hydrolysis, whereas fosinoprilat was slightly more specific for the N-domain. The in vivo selective inhibitory potency of single oral doses of 10 mg omapatrilat and 20 mg fosinopril were investigated in a double-blind, placebo-controlled, cross-over study in 9 mildly sodium-depleted normotensive subjects. In accordance with the in vitro results, fosinopril appeared to be more specific for the N-domain than the C-domain in vivo, since plasma and urine AcSDKP concentrations were significantly higher than those observed with omapatrilat. This study shows that it is possible to assess separately in vitro and in vivo the selectivity of ACE or ACE/neutral endopeptidase inhibitors. A differential selectivity may explain some peculiar properties observed with some ACE inhibitors.Keywords
This publication has 11 references indexed in Scilit:
- Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lungPublished by Elsevier ,2002
- RXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sitesProceedings of the National Academy of Sciences, 1999
- Pharmacodynamic effects of dual neutral endopeptidase–angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humansClinical Pharmacology & Therapeutics, 1999
- Effects of Omapatrilat in Low, Normal, and High Renin Experimental HypertensionAmerican Journal of Hypertension, 1998
- Substrate Dependence of Angiotensin I-Converting Enzyme Inhibition: Captopril Displays a Partial Selectivity for Inhibition ofN-Acetyl-Seryl-Aspartyl-Lysyl-Proline Hydrolysis Compared with That of Angiotensin I·Molecular Pharmacology, 1997
- Differences in the hydrolysis of enkephalin congeners by the two domains of angiotensin converting enzymeBiochemical Pharmacology, 1997
- Dual Metalloprotease Inhibitors: Mercaptoacetyl-Based Fused Heterocyclic Dipeptide Mimetics as Inhibitors of Angiotensin-Converting Enzyme and Neutral EndopeptidaseJournal of Medicinal Chemistry, 1997
- Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline.Journal of Clinical Investigation, 1996
- The Hemoregulatory Peptide N-Acetyl-Ser-Asp-Lys-Pro Is a Natural and Specific Substrate of the N-terminal Active Site of Human Angiotensin-converting EnzymeJournal of Biological Chemistry, 1995
- Mixed inhibitors of angiotensin-converting enzyme (EC 3.4.15.1) and enkephalinase (EC 3.4.24.11): rational design, properties, and potential cardiovascular applications of glycopril and alatriopril.Proceedings of the National Academy of Sciences, 1991